Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Stocks · News reference
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425
HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.